Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO101 in mild to moderate hidradenitis suppurativa
NCT06645821Phase 1Recruiting
- Sponsor
- Virginia Clinical Research
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EVO101 in hidradenitis suppurativa (HS), sponsored by Virginia Clinical Research. Primary endpoints: Decrease in total hidradenitis suppurativa lesion count at 12 weeks and Change in patient reported outcomes at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
EVO101
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06645821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645821.